Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Accounts Payables (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Accounts Payables data on record, last reported at $6.6 million in Q1 2026.

  • On a quarterly basis, Accounts Payables rose 206.73% to $6.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.6 million, a 206.73% increase, with the full-year FY2025 number at $4.2 million, up 114.43% from a year prior.
  • Accounts Payables reached $6.6 million in Q1 2026 per RAPP's latest filing, up from $4.2 million in the prior quarter.
  • Over the last five years, Accounts Payables for RAPP hit a ceiling of $6.6 million in Q1 2026 and a floor of $1.3 million in Q3 2024.
  • A 4-year average of $3.0 million and a median of $2.5 million in 2023 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: dropped 21.9% in 2024, then skyrocketed 206.73% in 2026.
  • Tracing RAPP's Accounts Payables over 4 years: stood at $2.5 million in 2023, then dropped by 21.9% to $2.0 million in 2024, then surged by 114.43% to $4.2 million in 2025, then soared by 56.59% to $6.6 million in 2026.
  • Business Quant data shows Accounts Payables for RAPP at $6.6 million in Q1 2026, $4.2 million in Q4 2025, and $3.2 million in Q3 2025.